MSB mesoblast limited

0.62%

$1.62

MSB - a new dawn, page-1510

First 1510 Last

Share
Profile

Follow
Wilba32

7,579 Posts.

1798

05/05/25

17:13

Post #: 78925069
Share

Originally posted by Sven62: ↑

nosluggos don't forget

Ryoncil (remestemcel-L) is not the primary treatment for graft-versus-host disease (GVHD) in children. It is specifically approved for the treatment of steroid-refractory acute GVHD (aGVHD) in pediatric patients 2 months of age and older who have not responded to standard steroid treatment.

Steroids are the first line of therapy for GVHD. The newest strategies prior to prevent or treat GVJD include post-transplant cyclophosphamide (PtCy), abatacept (Orencia®), ruxolitinib (Jakafi®), ibrutinib (Imbruvica®) and belumosudil (Rezurock®).

Second-line therapy is considered when the first line fails, or GVHD symptoms flare or recur. Ruxolitinib is often used.

Ruxolitinib (Jakafi), Ibrutinib (Imbruvica), and Belumosudil (Rezurock) are all FDA-approved for the treatment of chronic GVHD. Axatilimab is not yet approved but has shown promising results. Currently, there are three drugs that are FDA-approved for use in secondary therapy in chronic GVHD.

Ryoncil is the third line of therapy and is expensive compared to Jakafi at $20,000 per month.

Mesoblast management on approval of Ryoncil were convinced there was significant pent up demand for Ryoncil and they set a price well above expectations. So far they have confirmed 5 patients after 4 1/2 months. The sales team at Mesoblast are working hard to change what people do in a real world practice and I believe they will get there. BUT I suspect they are finding it slower than they thought.

Anyone who has done a valuation on Mesoblast knows that the Ryoncil sales forecast is critical to the current share price in the absence of other FDA product confirmation or a partnership deal and that is why the share price trades where it is.

My Valuation for Ryoncil's valuation of $2.47 per share is shaky as it is pretty clear to me that they are unlikely to average 1.47 children per week for the June half 2025. I hope they are in a position to give some clarity on the run rate and ramp up of Ryoncil in the next few weeks!

Expand

I was pondering this today and realised that Rux is not FDA approved for children 11 & under.

Also, as a doctor (which I’m not) I would say Rux was too toxic (harmful) for any of my dying patients I.e.12 years & up.

Last edited by Wilba32: 05/05/25

MSB Price at posting: $1.80 Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

'Not possible' to port renewable gas: ACCC takes AGN to court

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

First 1510 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.62		Change 0.010(0.62%)		Mkt cap ! $2.070B

Open	High	Low	Value	Volume
$1.60	$1.66	$1.60	$6.344M	3.894M

Buyers (Bids)

No.	Vol.	Price($)
2	102178	$1.62

Sellers (Offers)

Price($)	Vol.	No.
$1.63	52607	2

View Market Depth

No.	Vol.	Price($)
2	102178	1.620
4	72690	1.615
4	62248	1.610
3	26172	1.605
9	64387	1.600

Price($)	Vol.	No.
1.625	52607	2
1.630	12693	2
1.635	26000	2
1.640	48772	3
1.645	23972	2

Last trade - 16.12pm 26/06/2025 (20 minute delay)

MSB (ASX) Chart

MSB - a new dawn, page-1510

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

'Not possible' to port renewable gas: ACCC takes AGN to court

Australia’s gas crisis is here – and dying coal plants aren’t helping

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MSB - a new dawn, page-1510

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

'Not possible' to port renewable gas: ACCC takes AGN to court

Australia’s gas crisis is here – and dying coal plants aren’t helping

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News